Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302
REDWOOD CITY, Calif., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results...



